Phaseline

Targets › HSV1

HSV1: drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 1, 1 Phase 4, 1 Phase 2; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: the race on HSV1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Sao Paulo General HospitalAcyclovir
Human herpesvirus 1 DNA polymerase inhibitor
HSV1, HSV2, VZVPhase 4Autoimmune Rheumatic DiseasesApr 2027
Shanghai BDgeneBD111
CRISPR/Cas9-based lentiviral particles targeting HSV-1 genes
HSV1Phase 2Herpes Simplex Virus Type I Stromal KeratitisDec 2026
David Baskin MDADV/HSV-tk
Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy; HSV-tk converts pr
HSV1Phase 1Glioblastoma MultiformeDec 2026

Conditions

Herpes Simplex Virus Type I Stromal Keratitis (2) Glioblastoma Multiforme (1) Autoimmune Rheumatic Diseases (1)

Modalities

other (1), small molecule (1), mixed (1)

Companies

David Baskin MD (1) University of Sao Paulo General Hospital (1) Shanghai BDgene (1)

Related targets

HSV2 (1) VZV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.